PMC:7556165 / 4161-4378 JSONTXT

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T26","span":{"begin":129,"end":139},"obj":"Species"},{"id":"T27","span":{"begin":129,"end":133},"obj":"Species"}],"attributes":[{"id":"A26","pred":"ncbi_taxonomy_id","subj":"T26","obj":"NCBItxid:2697049"},{"id":"A27","pred":"ncbi_taxonomy_id","subj":"T27","obj":"NCBItxid:694009"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T30","span":{"begin":34,"end":213},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T7","span":{"begin":47,"end":51},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0002398"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"145","span":{"begin":87,"end":91},"obj":"Gene"},{"id":"146","span":{"begin":107,"end":111},"obj":"Gene"},{"id":"147","span":{"begin":129,"end":139},"obj":"Species"}],"attributes":[{"id":"A145","pred":"pubann:denotes","subj":"145","obj":"Gene:59272"},{"id":"A146","pred":"pubann:denotes","subj":"146","obj":"Gene:59272"},{"id":"A147","pred":"pubann:denotes","subj":"147","obj":"Tax:2697049"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T531","span":{"begin":87,"end":91},"obj":"Protein"},{"id":"T532","span":{"begin":107,"end":111},"obj":"Protein"}],"attributes":[{"id":"A531","pred":"uniprot_id","subj":"T531","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"},{"id":"A532","pred":"uniprot_id","subj":"T532","obj":"https://www.uniprot.org/uniprot/Q9UFZ6"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T17","span":{"begin":3,"end":9},"obj":"http://purl.obolibrary.org/obo/BFO_0000030"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T18","span":{"begin":47,"end":51},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"fma_id","subj":"T18","obj":"http://purl.org/sig/ont/fma/fma9712"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T35","span":{"begin":129,"end":139},"obj":"Disease"},{"id":"T36","span":{"begin":129,"end":133},"obj":"Disease"}],"attributes":[{"id":"A35","pred":"mondo_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A36","pred":"mondo_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T7","span":{"begin":47,"end":51},"obj":"http://purl.obolibrary.org/obo/MAT_0000091"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-PubTator","denotations":[{"id":"145","span":{"begin":87,"end":91},"obj":"Gene"},{"id":"146","span":{"begin":107,"end":111},"obj":"Gene"},{"id":"147","span":{"begin":129,"end":139},"obj":"Species"}],"attributes":[{"id":"A145","pred":"tao:has_database_id","subj":"145","obj":"Gene:59272"},{"id":"A146","pred":"tao:has_database_id","subj":"146","obj":"Gene:59272"},{"id":"A147","pred":"tao:has_database_id","subj":"147","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}

{"project":"LitCovid-sentences","denotations":[{"id":"T30","span":{"begin":34,"end":213},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"he object of a major controversy. On the other hand, treatments able to interfere with ACE2 expression, or ACE2 availability for SARS-CoV-2 binding, have been identified as a novel goal of pharmaceutical research.\nThe"}